Clinical Trial of Helminth-induced Immunomodulatory Therapy (HINT 2) in Relapsing-Remitting Multiple Sclerosis (P3.149)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: To explore the safety and preliminary effectiveness of the helminth Trichuris suis ova (TSO) (porcine whipworm) in subjects with early relapsing-remitting multiple sclerosis (RRMS). BACKGROUND: The hygiene hypothesis suggests that the high level of sanitation in the modern environment (i.e., relative microbial deprivation) is one factor which may contribute to disordered immune regulation in putative autoimmune disorders, such as MS. DESIGN/METHODS: A baseline versus treatment design was employed in an exploratory clinical trial of 15 treatment naive, recently diagnosed RRMS subjects, each of whom underwent 5 months of pre-treatment observation and 10 months of treatment with TSO (2,500 live ova orally every two weeks). The primary outcome measures were 1) safety and tolerability of TSO and 2) changes in the number of gadolinium enhancing lesions (Gd+) during monthly brain MRI scans with double-dose gadolinium contrast which were read in random order by three masked radiologists. RESULTS: No significant safety or tolerability issues were observed. With 90% of timepoints analyzed to date, the mean number of Gd+ lesions per month was 3.2 during 5 months of observation and 2.1 during the last 5 months of treatment, a 34% relative reduction. Immunological assessments indicated that TSO was associated with increases in T regulatory cells and a modified Th2 immune response. Transcriptional analyses of peripheral blood mononuclear cells suggested that treatment led to diminished expression of the pellino E3 ubiquitin protein ligase 1 (pelli 1) gene, recently demonstrated to be a central activator of microglia in experimental autoimmune encephalomyelitis and possibly in MS itself. CONCLUSIONS: TSO appears safe and well-tolerated in RRMS subjects. The modest decrease observed in numbers of Gd+ lesions during treatment indicates that further studies if TSO will be required to assess its effectiveness in RRMS. Study Supported by: National Multiple Sclerosis Society Research Grant 3613A4/1
Disclosure: Dr. Fleming has nothing to disclose. Dr. Hartman has nothing to disclose. Dr. Maksimovic has nothing to disclose. Dr. Nace has nothing to disclose. Dr. Luzzio has nothing to disclose. Dr. Koehn has nothing to disclose. Dr. Ritter has nothing to disclose. Dr. Risa has nothing to disclose. Dr. Lawler has nothing to disclose. Dr. Maser has nothing to disclose. Dr. Mundt has nothing to disclose. Dr. Rolak has nothing to disclose. Dr. Cook has received personal compensation for activities with Biomarin, GlaxoSmithKline Inc., Zensun, Neuraltus, Merck & Co. Inc., and Advntrx. Dr. Field has nothing to disclose. Dr. Fabry has nothing to disclose.
Tuesday, April 29 2014, 3:00 pm-6:30 pm
- Copyright © 2014 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.